权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development and Utilization of Splice-specific Antibodies

剪接特异性抗体的开发和利用

基本信息

批准号：
10242818
负责人：
Rachel O'Neill
金额：
$ 16.91万
依托单位：
UNIVERSITY OF CONNECTICUT STORRS
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10242818
关键词：
Affinity Alternative Splicing Amino Acids Anti-Idiotypic Antibodies Antibodies Antigens Apoptosis Appearance Area Bacteriophages Biological Blood Vessels Brain Cell Cycle Progression Chimeric Proteins Code Detection Development Diagnostic Directed Molecular Evolution Enzyme Inhibitor Drugs Enzyme-Linked Immunosorbent Assay Epitopes Event Exons Flow Cytometry Generations Genes Human Human Genome Immune response Immunofluorescence Immunologic Immunoprecipitation Individual Legal patent Length Libraries Malignant Neoplasms Mass Spectrum Analysis Methods Modeling Neoplastic Processes Oncogenic Oncology Outcome Pathway interactions Peptides Phage Display Phenotype Physiological Processes Play Property Protein Isoforms Proteins Proteome RNA Splicing Reagent Regulation Research Risk Role Sampling Scientist Serine Side Single Nucleotide Polymorphism Site Specificity Structure Supporting Cell Survival Rate Technology Therapeutic Transcript Validation Variant Western Blotting angiogenesis anti-cancer antibody diagnostic anticancer research base cancer biomarkers cancer type centromere protein A cross reactivity design detection method improved in vivo inhibitor/antagonist innovation inorganic phosphate neurogenesis new technology novel novel strategies overexpression prognostic protein complex protein function protein protein interaction protein structure technique development technology development tumor tumorigenesis

项目摘要

ABSTRACT In the human genome, alternative splicing events facilitate the generation of a proteome with a greater diversity than is observed in the protein-coding gene repertoire. In other words, the vast majority of human genes can each produce numerous different transcripts and subsequently multiple protein isoforms. However, aberrant splicing can produce an increase in novel isoforms or normally low-level isoforms leading to potentially detrimental effects including altered protein function, protein- protein interactions as well as remodeling of protein complexes and pathways. In fact, the increase in these alternatively-spliced isoforms is now recognized as a major contributor to oncogenic phenotypes, such as the development of tumors and new blood vessels by supporting cell invasion and proliferation. A central challenge to realizing the biological impact, prognostic and therapeutic potential of alternatively-spliced isoforms across multiple cancer types has been a lack of technology available for unambiguously differentiating highly similar protein variants in their native forms. Current methods of detecting and studying alternatively-spliced isoforms at the protein level rely solely on indirect methods such as tag-based detection and nonspecific affinity reagents that are unable to discriminate among multiple protein isoforms. Herein, we propose a novel approach to develop highly specific antibodies against alternatively-spliced protein isoforms using a targeting method at the splice site junction with near amino acid specificity. With this technology, antibodies can be generated to specifically detect a desired, alternatively-spliced protein isoform without cross-reactivity to the native full-length form. This technological advance will accelerate oncology research and enable scientists to study both high-value and novel protein isoforms and their direct role in specific cancer phenotypes, metastatic potential, tumor grade specificity and survival rates, and provide a validation means for assessing the therapeutic potential of anticancer alternative-splicing inhibitors.

摘要